Impact BioMedical Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 333-275062Commission file number IMPACT BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) 85-3926944 (IRS EmployerIdentification No.) 1400 Broadfield Blvd., Suite 130,Houston, TX, 77084(Address of principal executive offices)(281) 415-6576(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files) Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒ Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes☐No☒ Securities registered pursuant to Section 12(b) of the Act: Title of each classTicker symbol(s)Name of each exchange on which registeredCommon Stock, $0.001 par value per shareN/AN/A As of May 5, 2026 there were 107,821,231 shares of the registrant’s common stock, $0.001 par value, outstanding. IMPACT BIOMEDICAL, INC.FORM 10-QTABLE OF CONTENTS PART IFINANCIAL INFORMATIONItem 1Condensed Consolidated Financial StatementsCondensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20252Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025(Unaudited)3Condensed Consolidated Statement of Changes in Stockholders’ (Deficit) Equity for the three months endedMarch 31, 2026 and 2025 (Unaudited)4Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025(Unaudited)5Notes to Interim Condensed Consolidated Financial Statements6Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 4Controls and Procedures20PART IIOTHER INFORMATION21Item 1Legal Proceedings21Item 1ARisk Factors21Item 2Unregistered Sales of Equity Securities and Use of Proceeds21Item 3Defaults upon Senior Securities21Item 4Mine Safety Disclosures21Item 5Other Information21Item 6Exhibits221 Table of Contents March 31, 2026(unaudited) Table of Contents Impact BioMedical, Inc. and SubsidiariesCondensed Consolidated Statements of Operations(unaudited) Table of Contents Table of Contents Impact BioMedical, Inc. and SubsidiariesCondensed Consolidated Statements of Cash FlowsFor the Three Months Ended March 31,(unaudited) Note 1. Nature of Operations and Basis of Presentation Nature of Operations Impact BioMedical, Inc., incorporated in the State of Nevada on October 16, 2018 (the “Company”, “Impact BioMedical”, “We”,“IBO”), discovers, confirms, and patents unique science and technologies which can be developed into new offerings in humanhealthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and otherrelationships. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, overthe counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological,oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential newofferings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors anddevelopment partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBOtechnologies in exchange for milestone, and royalty payments. Currently, our operations are conducted, and our assets are ownedthrough our principal sub